^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    leuprolide acetate for depot suspension

    i
    Other names: TAP-144-SR, TAP-144SR, TAP-144, TAP-144-SR (6M), DWJ 108J, PT105
    Company:
    Generic mfg.
    Drug class:
    GnRH agonist
    Related drugs:
    12d
    Successful management of refractory hyperprolactinemia secondary to ectopic prolactin-secreting disseminated peritoneal leiomyomatosis via surgical resection and postoperative leuprorelin therapy: a rare case report. (PubMed, Gynecol Pelvic Med)
    She received bromocriptine (up to 5 mg/day) for 6 months without response. Clinicians should consider extrapituitary prolactin-secreting lesions in patients with treatment-refractory hyperprolactinemia. Genetic evaluation may further elucidate the pathogenesis of such rare entities.
    Journal
    |
    PRLR (Prolactin Receptor 2)
    |
    leuprolide acetate for depot suspension
    17d
    CGVV858A12101: Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors (2025-521911-38-00)
    P1/2, N=55, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • letrozole • goserelin acetate • leuprolide acetate for depot suspension
    19d
    Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)" (clinicaltrials.gov)
    P=N/A, N=1905, Completed, Takeda | Recruiting --> Completed
    Trial completion
    |
    AR (Androgen receptor)
    |
    leuprolide acetate for depot suspension
    21d
    ADENOFERT: Assisted reproductive technology (ART) and pregnancy outcomes in women with adenomyosis (internal endometriosis) according to stimulation protocol in relation to immunological and endometrial features: a prospective, randomized study (2024-516089-12-00)
    P4, N=500, Recruiting, Azienda Ospedaliero Universitaria Di Modena | Not yet recruiting --> Recruiting
    Enrollment open
    |
    leuprolide acetate for depot suspension
    22d
    BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder (clinicaltrials.gov)
    P1/2, N=100, Not yet recruiting, University of Illinois at Chicago
    New P1/2 trial
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive
    |
    letrozole • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension
    25d
    CGVV858A12101: Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors (2025-521911-38-00)
    P1/2, N=55, Not yet recruiting, Novartis Pharma AG | N=26 --> 55
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • letrozole • goserelin acetate • leuprolide acetate for depot suspension
    1m
    ASCLEPIuS: A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (clinicaltrials.gov)
    P1/2, N=102, Active, not recruiting, University of Michigan Rogel Cancer Center | Trial completion date: May 2027 --> May 2029 | Trial primary completion date: Nov 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    DRD (DNA Repair Deficiency)
    |
    DDR
    |
    Zejula (niraparib) • abiraterone acetate • leuprolide acetate for depot suspension
    2ms
    Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect (clinicaltrials.gov)
    P=N/A, N=94, Recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Trial completion date: Apr 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    leuprolide acetate for depot suspension
    2ms
    Prostate cancer presenting as brain metastasis with concurrent elevation of carcinoembryonic antigen and carbohydrate antigen 19-9 levels: illustrative case. (PubMed, J Neurosurg Case Lessons)
    Brain metastases from prostate cancer with elevated CEA and CA19-9 are rare. Although these markers often indicate a poor prognosis, this patient achieved a favorable outcome with multimodal treatment. https://thejns.org/doi/10.3171/CASE25735.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CA 19-9 (Cancer antigen 19-9) • NKX3-1 (NK3 homeobox 1)
    |
    docetaxel • Nubeqa (darolutamide) • leuprolide acetate for depot suspension
    2ms
    Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (clinicaltrials.gov)
    P3, N=315, Active, not recruiting, AstraZeneca | Trial completion date: Nov 2027 --> Sep 2028
    Trial completion date • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HR positive • HER-2 negative • ESR1 mutation • HR positive + HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation • HER-2 negative + HR positive + ESR1 mutation
    |
    Guardant360® CDx
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • Etcamah (camizestrant) • goserelin acetate • leuprolide acetate for depot suspension
    2ms
    Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (clinicaltrials.gov)
    P2, N=532, Recruiting, Mayo Clinic | Trial completion date: May 2029 --> Feb 2031 | Trial primary completion date: May 2029 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    enzalutamide • abiraterone acetate • Nubeqa (darolutamide) • apalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    2ms
    CGVV858A12101: Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors (2025-521911-38-00)
    P1/2, N=26, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • letrozole • goserelin acetate • leuprolide acetate for depot suspension